Please use this identifier to cite or link to this item:
http://repositorio.insp.mx:8080/jspui/handle/20.500.12096/7892
Title: | Gene signature based on degradome-related genes can predict distal metastasis in cervical cancer patients |
Keywords: | Carcinoembryonic Antigen,Medical Oncology,Neoplasmsimmunologyalpha-Fetoproteins,Degradome, cervical cancer inhibitor proteases locally advanced cervical cancer metastasis molecular markers. |
Issue Date: | 2017 |
Publisher: | ESPM INSP |
Abstract: | Cervical cancer is one of the leading causes of death in women worldwide, which mainly affects developing countries. The patients who suffer a recurrence and/or progression disease have a higher risk of developing distal metastases. Proteases comprising the degradome given its ability to promote cell growth, migration, and invasion of tissues play an important role during tumor development and progression. In this study, we used high-density microarrays and quantitative reverse transcriptase polymerase chain reaction to evaluate the degradome profile and their inhibitors in 112 samples of patients diagnosed with locally advanced cervical cancer. Clinical follow-up was done during a period of 3 years. Using a correlation analysis between the response to treatment and the development of metastasis, we established a molecular signature comprising eight degradome-related genes (FAM111B, FAM111A, CFB, PSMB8, PSMB9, CASP7, PRSS16, and CD74) with the ability to discriminate patients at risk of distal metastases. In conclusion, present results show that molecular signature obtained from degradome genes can predict the possibility of metastasis in patients with locally advanced cervical cancer. |
URI: | sicabi.insp.mx:2017-None https://journals.sagepub.com/doi/pdf/10.1177/1010428317711895 https://www.doi.org/10.1177/1010428317711895 http://repositorio.insp.mx:8080/jspui/handle/20.500.12096/7892 |
Appears in Collections: | Artículos |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.